Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)
The purpose of this study is to determine if a single intravenous (IV) dose of palonosetron 0.25 mg plus a single IV dose of dexamethasone 8 mg is effective to prevent nausea and vomiting induced by moderately emetogenic chemotherapy in subjects with cancer.
Neoplasms|Nausea|Vomiting
DRUG: Palonosetron and Dexamethasone
Proportion of patients having achieved complete response (CR), defined as no emetic episodes and no rescue medication., During 24 hours after administration of chemotherapy.
Proportion of patients who achieved a CR and of those who achieved complete control; Number of emetic episodes; Time to first emetic episode, to administration and need for rescue therapy; and to treatment failure, Days 1 to 5 at different time intervals for each secondary outcome.|Severity of nausea; Patient global satisfaction; Quality of life questionnaire, Days 1 to 5 at different time intervals for each secondary outcome.
The purpose of this study is to determine if a single intravenous (IV) dose of palonosetron 0.25 mg plus a single IV dose of dexamethasone 8 mg is effective to prevent nausea and vomiting induced by moderately emetogenic chemotherapy in subjects with cancer.